Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786348 | 0.84 | NOS3 (0.36) | NOS3NOS1NOS2ALDH1A1GAA | |
| SCHEMBL15806351 | 0.81 | UHRF1 (0.32) | UHRF1AAK1 | |
| SCHEMBL9455739 | 0.81 | KDM4E (0.33) | UHRF1KDM4EALDH1A1GAAAAK1 | |
| SCHEMBL11981609 | 0.81 | APLNR (0.30) | UHRF1ALDH1A1 | |
| SCHEMBL15806350 | 0.81 | APLNR (0.30) | UHRF1ALDH1A1 | |
| SCHEMBL25098459 | 0.81 | UHRF1 (0.32) | UHRF1AAK1 | |
| SCHEMBL11981613 | 0.81 | UHRF1 (0.32) | UHRF1AAK1 | |
| SCHEMBL15277642 | 0.81 | APLNR (0.30) | UHRF1ALDH1A1 | |
| SCHEMBL23989533 | 0.78 | AAK1 (0.33) | UHRF1KDM4EALDH1A1GAAAAK1 | |
| SCHEMBL21091000 | 0.78 | UHRF1 (0.32) | UHRF1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-2078721-A2 | Thieno-pyrimidime compounds having fungicidal activity | Dow AgroSciences LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | GRUENENTHAL GMGH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7531482-B2 | Thieno-pyrimidine compounds having fungicidal activity | DOW AGROSCIENCES LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1937691-A1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | Dow Agrosciences LLC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | IRM LLC (BM) | 2007-08-16 | — | — | US | disclosed |
| US-20070093498-A1 | Thieno-pyrimidine compounds having fungicidal activity | BREWSTER WILLIAM K | 2007-04-26 | — | — | US | disclosed |
| WO-2007046809-A1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | NOS3 2866/4885NOS1 3050/4885NOS2 2708/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NOS3 403/4885NOS1 864/4885NOS2 433/4885 |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | NOS3 3259/4885NOS1 2106/4885NOS2 3694/4885 |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRM5, GRIK5, GRM1 | NOS3 4030/4885NOS1 4069/4885NOS2 3600/4885 |
| US-20070093498-A1 | Thieno-pyrimidine compounds having fungicidal activity | TYMP, DPM1, TYMS | NOS3 1682/4885NOS1 3071/4885NOS2 2840/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NOS3 2141/4885NOS1 3064/4885NOS2 2940/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NOS3 3935/4885NOS1 4188/4885NOS2 4063/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NOS3 1064/4885NOS1 1486/4885NOS2 1634/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | NOS3 1172/4885NOS1 1417/4885NOS2 1166/4885 |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | NOS3 288/4885NOS1 128/4885NOS2 157/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | NOS3 4820/4885NOS1 4856/4885NOS2 4840/4885 |
| US-20070191380-A1 | KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION | MAP2K2, MAP2K1, MAP2K7 | NOS3 1464/4885NOS1 1430/4885NOS2 1514/4885 |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | FIBP, PFAS, FPR3 | NOS3 1409/4885NOS1 2916/4885NOS2 2016/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | NOS3 826/4885NOS1 394/4885NOS2 589/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | NOS3 1318/4885NOS1 1279/4885NOS2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.